Ball Plans To Build New Aluminum Beverage Packaging Plants In UK & Russia To Meet Demand

Ball Corp. (BLL), a manufacturer of recyclable aluminium beverage packaging, Thursday said it is planning to significantly increase its manufacturing capacity, amid increasing demand for aluminium packaging. The company intends to build new aluminum beverage packaging plants in UK & Russia.

From 2023, each facility would produce billions of cans a year across a range of formats and sizes, and provide up to 200 skilled jobs in a fast-growing but stable sector.

The company said the plan reflects requirement for more sustainable purchasing options and a growing number of new brands and beverage categories choosing cans.

In the UK, Ball has identified a site at the SEGRO Park Kettering Gateway, and has submitted its formal application to North Northamptonshire Council . The company expects breaking ground during 2021, following a period of public consultation. It will the company's third beverage can manufacturing facility in the UK.

Further, Ball is planning to build a plant in Ulyanovsk in Western Russia. Ball Beverage Packaging Naro-Fominsk has signed a cooperation agreement for its construction with the Ulyanovsk Regional Government. The Ulynavosk plant will take the total in Russia to four.

The company noted that aluminium drinks cans are the world's most widely recycled beverage packaging with an 82% recycling rate in the UK and 76% across Europe.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT